Susan P. Whitman

Best Publications

• IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

  Guido Marcucci;Kati Maharry;Yue-Zhong Wu;Michael D. Radmacher

  921
  Citations

• Absence of the Wild-Type Allele Predicts Poor Prognosis in Adult de Novo Acute Myeloid Leukemia with Normal Cytogenetics and the Internal Tandem Duplication of FLT3 A Cancer and Leukemia Group B Study

  Susan P. Whitman;Kellie J. Archer;Lan Feng;Claudia Baldus

  905
  Citations

• Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

  Krzysztof Mrózek;Guido Marcucci;Peter Paschka;Susan P. Whitman

  773
  Citations

• MicroRNA expression in cytogenetically normal acute myeloid leukemia

  Guido Marcucci;Michael D. Radmacher;Michael D. Radmacher;Kati Maharry;Kati Maharry;Krzysztof Mrózek

  535
  Citations

• Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

  Krzysztof Mrózek;Guido Marcucci;Deedra Nicolet;Kati S. Maharry

  512
  Citations

• An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.

  Klaus H. Metzeler;Manuela Hummel;Clara D. Bloomfield;Karsten Spiekermann

  456
  Citations

• Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

  Heiko Becker;Guido Marcucci;Kati Maharry;Michael D. Radmacher

  451
  Citations

• Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

  Guido Marcucci;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  434
  Citations

• TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

  Klaus H. Metzeler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  419
  Citations

• FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

  Susan P. Whitman;Amy S. Ruppert;Amy S. Ruppert;Michael D. Radmacher;Michael D. Radmacher;Krzysztof Mrózek

  346
  Citations

• ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

  Klaus H. Metzeler;Heiko Becker;Kati Maharry;Kati Maharry;Michael D. Radmacher;Michael D. Radmacher

  332
  Citations

• Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

  Guido Marcucci;Klaus H. Metzeler;Sebastian Schwind;Heiko Becker

  332
  Citations

• RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

  Jason H. Mendler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  324
  Citations

• Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

  Peter Paschka;Guido Marcucci;Amy S. Ruppert;Susan P. Whitman

  322
  Citations

• BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

  Claudia D. Baldus;Stephan M. Tanner;Amy S. Ruppert;Susan P. Whitman

  315
  Citations

• Sp1/NFκB/HDAC/miR-29b Regulatory Network in KIT-Driven Myeloid Leukemia

  Shujun Liu;Lai Chu Wu;Jiuxia Pang;Ramasamy Santhanam

  301
  Citations

• Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study

  Guido Marcucci;Claudia D. Baldus;Amy S. Ruppert;Michael D. Radmacher

  299
  Citations

• FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

  Susan P. Whitman;Kati Maharry;Kati Maharry;Michael D. Radmacher;Michael D. Radmacher;Heiko Becker

  281
  Citations

• High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

  Guido Marcucci;Kati Maharry;Susan P. Whitman;Tamara Vukosavljevic

  272
  Citations

• High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

  Christian Langer;Michael D. Radmacher;Amy S. Ruppert;Susan P. Whitman

  261
  Citations